Literature DB >> 8236454

Inhibitors of Ras farnesyltransferases.

F Tamanoi1.   

Abstract

Farnesyltransferase catalyses the post-translational modification of proteins by a cholesterol precursor, farnesylpyrophosphate. One of the substrates of this enzyme is the product of the ras oncogene. Recently, inhibitors of farnesyltransferase have been identified through two different approaches: microbial screens for natural compounds, and substrate analogues. These inhibitors may be useful in blocking the action of Ras proteins, in further characterizing protein prenyltransferases, and in elucidating the regulation of cholesterol metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236454     DOI: 10.1016/0968-0004(93)90072-u

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  22 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

4.  Protein farnesyltransferase in plants: molecular characterization and involvement in cell cycle control.

Authors:  D Qian; D Zhou; R Ju; C L Cramer; Z Yang
Journal:  Plant Cell       Date:  1996-12       Impact factor: 11.277

5.  Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner.

Authors:  Y Sohara; N Ishiguro; K Machida; H Kurata; A A Thant; T Senga; S Matsuda; K Kimata; H Iwata; M Hamaguchi
Journal:  Mol Biol Cell       Date:  2001-06       Impact factor: 4.138

6.  Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.

Authors:  Shao H Yang; Sandy Y Chang; Yiping Tu; Gregory W Lawson; Martin O Bergo; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2011-10-28       Impact factor: 5.922

7.  Mutant farnesyltransferase beta subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I beta subunit.

Authors:  H Mitsuzawa; K Esson; F Tamanoi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Actinoplanic acids A and B as novel inhibitors of farnesyl-protein transferase.

Authors:  K C Silverman; C Cascales; O Genilloud; J M Sigmund; S E Gartner; G E Koch; M M Gagliardi; B K Heimbuch; M Nallin-Omstead; M Sanchez
Journal:  Appl Microbiol Biotechnol       Date:  1995 Aug-Sep       Impact factor: 4.813

9.  Proteins prenylated by type I protein geranylgeranyltransferase act positively on the jasmonate signalling pathway triggering the biosynthesis of monoterpene indole alkaloids in Catharanthus roseus.

Authors:  Vincent Courdavault; Vincent Burlat; Benoit St-Pierre; Nathalie Giglioli-Guivarc'h
Journal:  Plant Cell Rep       Date:  2008-09-24       Impact factor: 4.570

Review 10.  Farnesyltransferase inhibitors and anti-Ras therapy.

Authors:  J B Gibbs; N E Kohl; K S Koblan; C A Omer; L Sepp-Lorenzino; N Rosen; N J Anthony; M W Conner; S J deSolms; T M Williams; S L Graham; G D Hartman; A Oliff
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.